INTRODUCTION {#s1}
============

Catecholaminergic polymorphic ventricular tachycardia (CPVT; MIM \#604772), a potentially fatal cardiac arrhythmia, is a genetic disorder characterized by stress-induced syncope and/or sudden death in juveniles and young adults in the absence of structural alteration of the heart ([@DDS104C1],[@DDS104C2]). The two genes currently associated with CPVT, ryanodine receptor (*RYR2*) and calsequestrin (*CASQ2*), encode proteins responsible for sarcoplamic reticulum (SR) calcium release during cardiac muscle contraction. They belong to the macromolecular calcium release complex (CRC), composed mainly of following proteins: the SR calcium release channel ryanodine receptor (RyR2); the CSQ2, which acts as a calcium buffer inside the SR; triadin and junctin, two proteins that have been implicated in anchoring CSQ2 to RyR2, at the terminal cisternae of SR ([@DDS104C3],[@DDS104C4]). Mutations have been identified in *RYR2* and *CASQ2* in only 70% of the patients affected by CPVT, indicating that other genes are involved in this disease. Therefore, the genes encoding triadin or junctin, the two linkers between RyR2 and CSQ2, naturally appeared as interesting candidate genes for CPVT.

Triadin is a multiprotein family arising from the alternative splicing of a single *TRDN* gene (MIM \#603283) localized on Chr6 and containing 41 exons ([@DDS104C5]). Two isoforms, Trisk 95 and Trisk 51, are exclusively expressed in skeletal muscle. A third one, Trisk 32 (also called CT1), is expressed mainly in cardiac muscle ([@DDS104C6]). Two triadin knock-out (KO) mouse models have been developed, presenting with cardiac arrhythmia and skeletal muscle weakness ([@DDS104C7]--[@DDS104C9]). Therefore, the presence of triadin seems essential for normal cardiac and skeletal muscle function.

Junctin, a 26 kDa protein expressed both in skeletal and cardiac muscle ([@DDS104C10]) (MIM \#600582), is an alternative splice product of the aspartyl-β-hydroxylase gene on Chr8 \[*ASPH*, ([@DDS104C11])\]. Two junctin isoforms are expressed in human cardiac muscle ([@DDS104C12]). Junctin is involved in regulation of the calcium homeostasis, and deletion of junctin in a mouse model results in fatal arrhythmia ([@DDS104C13]).

This study presents the molecular investigations performed in a large panel of well-characterized CPVT patients in which mutations in *RYR2* and *CASQ2* genes had been excluded. Pathophysiological and clinical consequences of the mutations identified in the *TRDN* gene in two families have been analyzed and will be discussed.

RESULTS {#s2}
=======

Clinical phenotype {#s2a}
------------------

The proband of family 1 (ind II:1, Fig. [1](#DDS104F1){ref-type="fig"}) originated from French West Indies. He was a 2-year-old boy who experienced syncope followed by cardiac arrest after a shock while playing with his 7-year-old brother. Resting electrocardiogram following cardiac resuscitation showed numerous polymorphic or bidirectional ventricular extra beats and runs of polymorphic ventricular tachycardia ([Supplementary Material, Fig. S1a](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). He died in the hospital 3 weeks following the initial cardiac arrest after a severe post-anoxic coma. There was no positive family history. The parents and the brother of the proband were considered healthy as their resting ECG, Holter recordings and exercise stress tests did not show any abnormality. Figure 1.Triadin mutations in two CPVT families. (**A**) Pedigrees of the two CPVT families. Filled squares indicated affected individuals and half filled symbols individuals heterozygous for a mutation. The proband in each Family is indicated by the black arrow. The genotype for each individual concerning the identified mutation is indicated as follow: '+' in the presence of the mutation and '−' in the absence of the mutation. (**B**) Membrane topology of cardiac isoform of triadin, Trisk 32, in the sarcoplasmic reticulum membrane with the localization of the three identified mutations. The 'KEKE' region is the interaction domain with RyR2 and CSQ2. Trisk 32 has a C-terminal specific region from amino acid 264--286.

The proband of Family 2 (ind II:2, Fig. [1](#DDS104F1){ref-type="fig"}) originated from Western France. He was a 26-year-old man who presented with recurrent syncopes at exercise since the infancy. Resting ECG was normal with no prolongation of the QT interval. Exercise testing showed numerous bidirectional ventricular extra beats ([Supplementary Material, Fig. S1b](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). The patient also presented with proximal muscle weakness. CPVT was also diagnosed in his dizygotic twin-brother (ind II:3) after clinical examination. They were both treated by nadolol 40 mg/day, a non-selective β-blocker. Clinical evaluation, Holter recording and exercise testing did not show any abnormalities among other family members investigated (ind II:1 and III:1).

Genetic analysis {#s2b}
----------------

Molecular analysis of the *TRDN* gene in Family 1 identified a c.del53_56ACAG homozygous deletion in exon 2. This deletion of four nucleotides resulted in a frameshift in the amino acid sequence from amino acid 18 leading to a premature termination codon (PTC) at position 31, designed p.D18Afs\*13 according to the nomenclature proposed by the Human Genome Variation Society ([@DDS104C14]) (<http://www.hgvs.org/mutnomen/recs-prot.html>). This mutation was identified at a heterozygous state in the three unaffected relatives tested (Fig. [1](#DDS104F1){ref-type="fig"}A). Haplotype analyses were performed in the family using polymorphic markers flanking the *TRDN* gene (cen-D6S1712-D6S979-TRDN-D6S1639-D6S408-tel) and were suggestive of a remote common ancestor.

Molecular analysis in Family 2 revealed that the two affected individuals II:2 and II:3 were compound heterozygous for a c.176C\>G missense mutation in exon 2 that led to the substitution of a threonine by an arginyl residue at position 59 (p.T59R) and a c.613C\>T nonsense mutation in exon 8 that introduced a PTC at position 205 in the amino acid sequence (p.Q205\*). Unaffected individuals tested carried one (ind III:1) or no variant (ind II:1) (Fig. [1](#DDS104F1){ref-type="fig"}A).

In both the families, the phenotype--genotype analysis was in favor of a recessive form of CVPT. The frameshift deletion c.del53_56delACAG; p.D18Afs\*13 inducing a stop codon in position 31 would result in deletion of the major part of the protein, and the production of a short cytosolic peptide as the stop was located before the transmembrane helix (Fig. [1](#DDS104F1){ref-type="fig"}B). The nonsense variation c.613C\>T; p.Q205\* generated a stop codon in position 205, just before the KEKE motif (domain composed of repetition of Lys and Glu) ([@DDS104C15]) located in position 210--224 responsible for interaction of Trisk 32 with RyR2 and CSQ2 ([@DDS104C16],[@DDS104C17]). These two mutations resulting into a PTC were clearly pathogenic because they would lead either to an absence of protein synthesis via nonsense-mediated mRNA decay ([@DDS104C18]), or to the production of a non-functional protein. The p.T59R variation affected a well-conserved position in Trisk 32 and resulted in the introduction of a positively charged amino acid in the transmembrane domain of the protein. The deleterious effect of the substitution within the transmembrane domain of this conserved threonine at position 59 by an arginine was less predictable and was thus further studied.

Localization of the mutant p.T59R in a model cell line {#s2c}
------------------------------------------------------

The effect of the p.T59R mutation on the behavior of Trisk 32 was first studied by expression in the non-muscle COS-7 cell line, and analysis of the localization of the wild-type (WT) (T32) or mutant protein (T32-T59R) by confocal microscopy. When expressed in COS-7 cells, the WT Trisk 32 was localized in the plasma membrane of 83% of the cells (Fig. [2](#DDS104F2){ref-type="fig"}A, panel PM) and in the endoplasmic reticulum for the remaining 17% of the cells (Fig. [2](#DDS104F2){ref-type="fig"}A, panel ER) (*n* = 500 cells). The p.T59R mutation induced the exclusive localization of Trisk 32 in an intracellular compartment (100%, *n* = 500 cells), identified as endoplasmic reticulum by co-localization with the endoplasmic reticulum (ER) resident protein calnexin ([Supplementary Material, Fig. S2a](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). This observation was confirmed by differential immunofluorescent labeling before and after permeabilization of the cells (Fig. [2](#DDS104F2){ref-type="fig"}B). Whereas Trisk 32 was labeled both on intact and permeabilized cells, confirming its plasma membrane localization, the mutant Trisk 32-T59R was accessible only after permeabilization thus indicating an intracellular retention. This intracellular retention was also confirmed by biotinylation of cell surface proteins ([Supplementary Material, Fig. S2b](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). Figure 2.Trisk 32 and Trisk 32-T59R cell localizations are different. (**A**) Trisk 32-T59R is located only at the endoplasmic reticulum, whereas Trisk 32 is mainly at the plasma membrane. WT Trisk 32 (T32) and mutant Trisk 32-T59R (T32--T59R) were transfected in COS-7 cells, and their localization analyzed by immunofluorescent labeling. Typical Trisk 32 labeling at the plasma membrane (PM) or in the ER are shown. Bar: 20 µm. The histogram shows the percentage of transfected cells exhibiting PM (closed square) or ER (open square) labeling, for a total of 500 transfected cells from three different experiments. \*\*\**P* \< 0.001, Fisher\'s test comparison of T32- vs. T32--T59R-transfected cells. (**B**) Immunofluorescent labeling on intact or permeabilized cells shows intracellular retention of Trisk 32-T59R. Transfected cells were fixed without permeabilization and stained with an antibody directed against the C-terminal end of Trisk 32, which is extracellular when the protein is in the plasma membrane (left panels, 'intact'). Afterwards, cells were permeabilized and stained with an antibody directed against the N-terminal end of Trisk 32, which is cytosolic when the protein is in the plasma membrane or in the reticulum membrane (right panels, 'permeabilized'). Bar: 20 µm.

Stability of the mutant Trisk 32-T59R in a model cell line {#s2d}
----------------------------------------------------------

As a lower level of expression of Trisk 32-T59R was observed in COS-7 cells compared with the WT Trisk 32, the stability of the mutant protein was evaluated. After transfection in COS-7 cells, Trisk 32 and Trisk 32-T59R appeared as a triple band of centered on 37 kDa, due to post-translational modification (glycosylation), as observed previously ([@DDS104C19],[@DDS104C20]). Transfected cells were incubated with cycloheximide (CHX), a protein synthesis inhibitor, and the amounts of Trisk 32 and Trisk 32-T59R were analyzed by quantitative western blotting after various incubation times. The relative amount of Trisk 32-T59R decreased faster than the relative amount of Trisk 32 (Fig. [3](#DDS104F3){ref-type="fig"}A), indicating a faster turnover of the mutant Trisk 32-T59R compared with the WT Trisk 32. This suggested that the abnormal localization observed for Trisk 32-T59R could result in protein instability and degradation. This degradation was further analyzed by proteasome inhibition by MG132. Proteasome inhibition did not increase the total amount of the WT Trisk 32, but it raised the amount of the mutant Trisk 32-T59R by 148% (Fig. [3](#DDS104F3){ref-type="fig"}B). This showed that Trisk 32-T59R was targeted for proteasome-mediated degradation. Altogether, results in COS-7 cells showed that mutant Trisk 32-T59R was unable to exit ER after synthesis and was prone to degradation most probably via the proteasomal pathway. Figure 3.The mutant protein Trisk 32-T59R is degraded faster, via the proteasome. (**A**) Trisk 32-T59R is degraded faster in the course of protein synthesis inhibition. WT Trisk 32 (T32) and mutant Trisk 32-T59R (T32-T59R) were first transfected in COS-7 cells. Transfected cells were then incubated with cycloheximine (CHX) to block protein synthesis for the indicated time. Cells were collected and analyzed by quantitative western blot with specific antibodies to evaluate the amount of protein. The curves show the quantification from four experiments of the amount of each protein (T32 -•- and T32-T59R -□-) compared with its initial amount. \*\*\**P* \< 0.001, *F*-test comparison of the two curves, based on decay and plateau parameters. (**B**) Inhibition of the proteasome raises the amount of the mutant protein Trisk 32-T59R. Twenty hours after transfection, the cells were incubated during 6 h with either dimethyl sulfoxide (DMSO) alone for controls (lanes '−') or 50 µ[m]{.smallcaps} MG132 to block proteasome (lanes '+'). The cells were then collected and analyzed by quantitative western blot with specific antibodies. The top panel shows a typical western blot, the bottom histogram (▪ DMSO; □ MG132) is a quantification (mean ± SEM) from three experiments. \**P* \< 0.05, Mann and Whitney test comparison of DMSO- vs. MG132-treated cells.

Stability and localization of the mutant Trisk 32-T59R after *in vivo* expression {#s2e}
---------------------------------------------------------------------------------

The behavior of the mutant Trisk 32-T59R was further studied after re-expression in the triadin KO mouse. The triadin KO mouse, a mouse line devoid of any triadin isoform, has been previously shown to present both cardiac arrhythmia ([@DDS104C8]) and muscle weakness ([@DDS104C9]). Viruses \[AAV2/9, which preferentially target the heart in adult mice ([@DDS104C21],[@DDS104C22])\] were developed to induce *in vivo* expression of the WT and mutant Trisk 32 proteins in the heart of triadin KO mice. One month after systemic injection of the viral vectors, the cardiomyocytes were isolated and characterized by different methodological approaches. The mRNA expression levels studied by semi-quantitative reverse transcription polymerase chain reaction (RT--PCR) of the WT Trisk 32 and the mutant Trisk 32-T59R were similar (Fig. [4](#DDS104F4){ref-type="fig"}A), showing that the mutation did not affect transcript stability. In contrast, the determination of the protein expression levels by quantitative western blot on cardiomyocytes homogenates (Fig. [4](#DDS104F4){ref-type="fig"}B) showed that no mutant protein could be detected in any of the six transduced mice, whereas the transduced WT Trisk 32 was detected in all the mice (Fig. [4](#DDS104F4){ref-type="fig"}B and [Supplementary Material, Fig. S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). This difference in expression was confirmed by immunofluorescence labeling on fixed cardiomyocytes (Fig. [5](#DDS104F5){ref-type="fig"}). In WT cardiomyocytes (Fig. [5](#DDS104F5){ref-type="fig"}A--C), Trisk 32 presented a typical dyad labeling, a row of dots co-localized with RyR2. In the triadin KO cardiomyocytes (Fig. [5](#DDS104F5){ref-type="fig"}D--F), Trisk 32 labeling was absent and RyR2 labeling was not modified. After transduction of Trisk 32 or Trisk 32-T59R in the triadin KO mice, only the transduced WT Trisk 32 was detected, in the dyads of cardiomyocytes, where it perfectly colocalized with RyR2 (Fig. [5](#DDS104F5){ref-type="fig"}G--I) while the transduced mutant Trisk 32-T59R was not detectable (Fig. [5](#DDS104F5){ref-type="fig"}J--L). This suggests although the mRNA of Trisk 32-T59R is expressed in the cardiomyocytes of the mice, the protein is absent. Figure 4.Stability analyses of transcripts and proteins after *in vivo* expression in triadin KO mice. (**A**) The mutant transcript is present at similar levels as the WT one. Messenger RNAs were purified from isolated cardiomyocytes of transduced mice. After reverse transcription, the cDNAs were either directly used or diluted 10 or 100 times before the PCR amplification of Trisk 32 (T32) and GAPDH. PCR products for Trisk 32 and GAPDH amplification were expected, respectively, at 250 and 136 bp. The PCR primers for GAPDH were designed to co-amplify possible contaminating genomic DNA as a 220 bp fragment, which was not observed. (**B**) The mutant protein Trisk 32-T59R was not detectable. Western blot analysis of 100 µg of cardiomyocytes homogenates from control WT mouse, with mouse-specific anti-Trisk 32 antibody (first lane), or 100 µg of cardiomyocytes from a Trisk 32-transduced mouse (second lane), or Trisk 32-T59R-transduced mouse (third lane) with rat-specific anti-Trisk 32 antibody. Trisk 32 appears as multiple bands (2/3) centered on 37 kDa, the higher bands, the glycosylated forms of Trisk 32, being in lower amount and visible in correlation with the intensity of the signal, as described before ([@DDS104C6],[@DDS104C20]). Figure 5.Immunofluorescent analysis of Trisk 32 in isolated cardiomyocytes. Cardiomyocytes were isolated from a WT mouse, a triadin KO mouse (KO), a triadin KO mouse transduced with rat Trisk 32 (KO + T32) and a triadin KO mouse transduced with rat Trisk 32-T59R (KO + T32-T59R). They were labeled with antibodies against mouse Trisk 32 and RyR (**A**--**F**) or against rat Trisk 32 and RyR (**G**--**L**). In all cardiomyocytes, RyR labeling is typical of a dyad labeling showing aligned rows of dots, as observed in the inserts. Bar: 2 µm.

DISCUSSION {#s3}
==========

CPVT is a life-threatening inheritable disease that predisposes young individuals with normal cardiac structure to cardiac arrest. Pre-symptomatic genetic screening is of major importance for CPVT families, since life-saving preventive treatments are available. Therefore, the identification of causative mutations constitutes a major issue for CPVT families. Up to now, two genes have been involved in this disease. They encode proteins which constitute the core of the cardiac CRC: RyR2 in the dominant forms of CPVT and CSQ2 in the recessive forms. However, almost one-third of the patients remained without an identified molecular defect. In the present work, we searched for mutations in other genes in a panel of 97 CVPT patients without mutations in the *RYR2* and *CASQ2* genes. We focused our screening on triadin and junctin which are the physiological partners of RyR2 and CSQ2 in the CRC. No mutation was identified in junctin, whereas three mutations were identified in triadin. The characterization of the physiopathological mechanisms is of uppermost importance for a better understanding of the disease and for the development of new therapies, as the current therapies are not fully satisfying ([@DDS104C1]). Along this line, we searched for the functional consequences of the *TRDN* mutations. Two of these mutations resulted in a premature stop codon, and the corresponding proteins are most probably not produced as a consequence of NMD ([@DDS104C18]). Thus, we focused our investigation on the third mutation, the missense p.T59R.

To study the consequences of this mutation, we analyzed the localization and the stability of the mutant protein in COS-7 cells and in cardiomyocytes. All the experiments we performed, either in transfected COS-7 cells or in cardiomyocytes from triadin KO mice transduced *in vivo*, showed that the p.T59R mutation resulted in instability of the protein, leading to its degradation. It would be interesting in this context to assay the ability of blockers of ER quality control or of molecular chaperones to restore the folding of Trisk 32-T59R and its correct targeting instead of its degradation, as done for α-sarcoglycan mutations in Limb Girdle Muscular Dystrophy type 2D ([@DDS104C23],[@DDS104C24]). The likely absence of the protein as a result of the mutation in patient\'s heart could only be further confirmed by western blot on a cardiac biopsy, which was not available. As the two other mutations (p.D18Afs\*13, homozygous mutation in Family 1 and p.Q205\*, compound heterozygous mutation associated to p.T59R in Family 2) most likely resulted in the absence of the protein, all the affected patients in this study can be considered natural triadin KO cases. The severe CPVT phenotype observed in these patients thus highlights the role of triadin in the regulation of the calcium release during cardiac contraction. In addition, the identified mutations mapped to a region of the *TRDN* gene which is common to all triadin isoforms, including the skeletal muscle Trisk 95 and Trisk 51. Thus, these three mutations would also lead to an absence of triadin in the skeletal muscle. This would give a possible explanation for the associated muscle weakness that was clinically observed in individual II:2 in Family 2. The affected patient in Family 1 died so young (2 years) that muscle weakness could not have been detected, but it could be envisaged that CPVT related to triadin mutation systematically affect both cardiac and skeletal muscle. Therefore, when a CPVT patient presents also with a moderate muscle weakness, screening of the *TRDN* gene should be performed at first. In this context, the triadin KO mouse is a good model to study the consequences of triadin deletion in human, as it presents with the same disease hallmarks: muscle weakness ([@DDS104C9]) and cardiac arrhythmia induced by β-adrenergic stimulation ([@DDS104C8]). Different mechanisms have been proposed to explain the cardiac arrhythmia resulting of *RYR2* or *CASQ2* mutations ([@DDS104C2],[@DDS104C25]). Among the possible mechanisms, one is related to the dissociation of FKBP12.6 from RyR2 in the case of *RYR2* mutation, which would result in a leaky Ca^2+^ channel ([@DDS104C26]). This mechanism could be envisaged for the triadin deletion resulting from the mutations identified in the present study, as it has been proposed in the triadin KO mouse that triadin ablation could impair FKBP12/RyR1 interaction in skeletal muscle ([@DDS104C27]). Such a hypothesis should nevertheless be confirmed in the heart for FKBP12.6/RyR2 interaction. Another mechanism proposed as a result of *CASQ2* mutations is a reduction in the amount of CSQ2 or in the calcium-binding capacity of the mutant CSQ2. Such a mechanism could also be proposed in the case of the identified triadin mutations, as a CSQ2 reduction has been observed in the triadin KO mouse heart ([@DDS104C8]). Therefore, the triadin mutations identified in the present study and the characterization of the triadin KO mice lines performed previously ([@DDS104C8],[@DDS104C9]) confirmed the hypothesis that CPVT could be more generally the result of a functional defect in the CRC ([@DDS104C2],[@DDS104C28]). Our study clearly showed that mutations in the *TRDN* gene are responsible for CPVT in the human and is therefore a gene to systematically investigate when screening familial CPVT. Nevertheless, the absence of mutation in *RYR2*, *CASQ2*, *ASPH* and *TRDN* in the 94 remaining patients of this cohort points to the limitation of the gene candidate approach. To search for other genes that might be involved, a large-scale screening should be performed in these patients. Finally, this paper described for the first time an involvement of the *TRDN* gene in human pathology, and interestingly, although this gene encodes for cardiac and muscle triadins, the pathology is mainly a cardiac one.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4a}
----------------

Investigations of patient population reported in the paper received a formal approval from the Regional Medical Ethical Committee (Comité de Protection des Personnes, CHU de Saint-Etienne; France). All procedures using animals were approved by the Institutional ethics committee and followed the guidelines of the National Research Council Guide for the care and use of laboratory animals.

Clinical evaluation of probands {#s4b}
-------------------------------

The patient population consisted in 97 CPVT probands carefully characterized after clinical examination and electrocardiographic records. Referred to the clinical centers for syncope with or without seizures, or cardiac arrest, they have been diagnosed on the basis of typical polymorphic ventricular arrhythmia recorded on 12-lead ECG, and after 24 h Holter ECG and exercise stress test. Family members were evaluated at least by resting ECG, and when possible a 24 h ECG Holter recordings and exercise stress test were performed.

Genetic analysis {#s4c}
----------------

Blood samples used for genetic evaluation were obtained after a written informed consent was signed by patients according to the French regulation for genetic studies. Molecular screening of *RYR2* and *CASQ2* genes has been performed as described before ([@DDS104C29]). Screening of the two junctin isoforms was performed by sequencing the six exons (NM_02164.4) corresponding to the longest isoform. Molecular analysis of the *TRDN* gene was performed by sequencing all the exons that encode the cardiac human isoform Trisk 32. Because of the large number of triadin transcripts described in the cardiac tissue originating from different species ([@DDS104C19],[@DDS104C30],[@DDS104C31]) without the experimental evidences for the existence of the corresponding proteins, we first characterized the human Trisk 32 sequence both at the cDNA and at the protein level using human cardiac tissue ([Supplementary Material, Fig. S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1) and [Supplementary Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). The presence of the corresponding protein was confirmed using an antibody developed against the specific C-terminal end of the identified sequence ([Supplementary Material, Fig. S4c](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1)). The sequence of human Trisk 32 identified in this study is accessible in GenBank database under accession number JN900469. Primers sequences used for molecular investigation of the *TRDN* and *ASPH* genes are listed in [Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1). Family members were screened for the mutation(s) identified in probands. A panel of 300 control chromosomes was screened for each novel variant reported in this study.

Plasmids, viruses and antibodies {#s4d}
--------------------------------

Full-length cDNA coding for rat Trisk 32 (accession number: EMBL AJ812276), with or without c.176C\>G mutation, corresponding to p.T59R change in the protein, was inserted into pcDNA3.1 (Invitrogen, Cergy Pontoise, France) for cell transfection, or in pZac2.1 for AAV development. The rat Trisk 32 nucleotide sequence used in this study has 84% identity with the human sequence and 92% with the mouse sequence, and was chosen because of the availability of efficient antibodies ([@DDS104C20]) developed in different species and necessary for the double immunofluorescent labeling. All viruses were engineered and produced by the Penn Vector Core (Philadelphia, PA, USA). Two recombinant adeno-associated viruses of serotype 2/9, encoding respectively the WT and the mutant T59R--Trisk 32 were used in this study: AAV-Trisk 32 and AAV-Trisk 32-T59R. All the transgenes were under the control of a CMV promoter.

Rabbit anti-RyR antibodies have been described previously ([@DDS104C32]), as well as rabbit anti-peptide antibodies against the N-terminal end of triadins ([@DDS104C33]), and anti-peptide antibodies against the rat Trisk 32 C-terminal end ([@DDS104C20]), developed in rabbit or guinea pig. We also used anti-peptide antibodies against the mouse Trisk 32 ([@DDS104C9]), and an anti-RyR developed in guinea pig by immunization with the C-terminal peptide of RyR1, as described before ([@DDS104C34]). The rabbit polyclonal antibody to calnexin (SPA-860) is from Stressgen (Victoria, Canada).

Cell culture, transfection and treatment {#s4e}
----------------------------------------

COS-7 cells were cultured in Dulbecco\'s modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen). Cells were transfected using Exgen 500 (Euromedex, Mundolsheim, France) for 28 h for immunofluorescent labeling experiments and for 20 h for western blot analysis after CHX or MG132 treatment.

For triadin stability experiment, transfected COS-7 cells were treated with 50 µg/ml of CHX for 0--6 h, or with 50 µ[m]{.smallcaps} MG132 for 6 h, or with 0.2% dimethyl sulfoxide (DMSO) for 6 h (control). Cells were then lysed with radioimmuno precipitation assay buffer \[25 m[m]{.smallcaps} Tris, pH 7.6, 150 m[m]{.smallcaps} NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)\], centrifuged and proteins in the supernatant were precipitated by chloroform/methanol for further analysis by quantitative western blot.

Immunofluorescent labeling on COS-7 cells and on cardiomyocytes {#s4f}
---------------------------------------------------------------

Transfected COS-7 cells were fixed either 6 min in cold methanol at −20°C, or 10 min in 4% paraformaldehyde (PFA). For detection of Trisk 32 at the cell surface, cells fixed with PFA were incubated with a guinea pig antibody against the C-terminus of rat Trisk 32. After permeabilization with 0.05% saponin, cells were incubated with a rabbit antibody against the N-terminus of rat Trisk 32 and then with secondary antibodies against both species.

Primary cardiomyocytes were seeded 1 h on laminin-coated glass cover slip, fixed 15 min in 4% PFA, permeabilized for 30 min in phosphate buffered saline (PBS)---0.5% Triton X-100, then saturated 1 h in PBS---0.1% Triton X-100---0.5% bovine serum albumin---2% goat serum, and incubated with primary antibodies.

The cells were observed under a LEICA SPE confocal microscope.

Mice and *in vivo* transduction {#s4g}
-------------------------------

Triadin KO mice developed on C57Bl6 background were described previously ([@DDS104C9]). Two-month-old triadin KO male mice (19--24 g) were anesthetized with xylazine (10 µg/g) and ketamine (100 µg/g), and injected with 2 × 10^11^ viral genome copy diluted in 100 µl of 150 m[m]{.smallcaps} NaCl, by a single injection in the tail vein.

Cardiomyocytes preparation {#s4h}
--------------------------

One month after virus injection, the hearts of transduced KO mice of non-transduced KO mice or of WT littermate mice were collected and cardiac ventricular myocytes were enzymatically dissociated as previously reported ([@DDS104C35]). Briefly, mice were euthanized by cervical dislocation, the heart rapidly excised and retrogradely perfused at 37°C for 6--8 min with a modified tyrode solution (in m[m]{.smallcaps}: NaCl 113, KCl 4.7, KH~2~PO~4~ 0.6, Na~2~HPO~4~ 0.6, MgSO~4~ 1.2, NaHCO~3~ 12, KHCO~3~ 10, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 10 Taurine 30, pH = 7.4) containing 0.1 mg/ml liberase (Roche, France). Isolated cardiomyocytes were then transferred to the same solution, free of enzyme, containing 1 m[m]{.smallcaps} CaCl~2~.

RT--PCR {#s4i}
-------

mRNA expression levels in transduced cardiomyocytes were determined by semi-quantitative RT--PCR. Briefly, total RNA was extracted from isolated cardiomyocytes using TRIzol Reagent and PureLink RNA Mini Kit (Invitrogen). First-strand cDNA was synthesized from 500 ng of total RNA using specific primer mixes followed by cDNA amplification. Primer sequences were as follows: rat Trisk 32: forward, 5′-AGCCAAAGAAACTCCGAAAA-3′; reverse, 5′-TCCAGTGGC CGTATGTACTTC-3′; mouse GAPDH: forward, 5′-CGTGCCGCCTGGAGAAAC-3′; reverse, 5′-TGGGAGTTGCTGTTGAAGTCG-3′. Equal amounts of cDNA were used in each reaction sample.

Western blot {#s4j}
------------

Cardiomyocytes or transfected cells were homogenized by 15 s sonication at 0°C in the presence of 1 m[m]{.smallcaps} DFP and 200 µ[m]{.smallcaps} PMSF as proteases inhibitors. One hundred micrograms of cardiomyocyte homogenates were analyzed by quantitative western blot analysis as described previously ([@DDS104C9]), with antibodies against rat Trisk 32 ([@DDS104C20]) or mouse Trisk 32 ([@DDS104C9]). Secondary antibodies used for western blot were labeled with horseradish peroxydase (Jackson ImmunoResearch Laboratories, Immunotech S.A.S., Marseille, France). The quantification was performed with a Chemidoc and the Quantity One software (BioRad, Marnes la Coquette, France).

Statistics {#s4k}
----------

Statistics were performed using either Fisher\'s test (Figs [2](#DDS104F2){ref-type="fig"}A and [3](#DDS104F3){ref-type="fig"}A) or Mann and Whitney\'s test (Fig. [3](#DDS104F3){ref-type="fig"}B) on Prism 4.0 software (GraphPad, San Diego, CA, USA).

SUPPLEMENTARY MATERIAL {#s5}
======================

[Supplementary Material is available at *HMG* online](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds104/-/DC1).
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